PLYMOUTH
MEETING, Pa., Nov. 6, 2024
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company
focused on developing and commercializing DNA medicines to help
treat and protect people from HPV-related diseases, cancer, and
infectious diseases, today announced that it will present at
the following scientific conferences:
36th International Papillomavirus Conference
(Edinburgh, UK; November 12-15)
Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences
Abstract Title: Treatment of recurrent respiratory
papillomatosis with INO-3107 induces significant
enrichment in hallmark interferon alpha, interferon gamma and
inflammatory molecular signatures in papilloma tissue of
responders
Poster by Dr. Jeffrey
Skolnik, SVP of Clinical Development
Abstract Title: Clinical response to INO-3107 treatment for
recurrent respiratory papillomatosis is associated with CD4 and CD8
T-Cell activity and cytotoxicity in patient airways
Vaccines Summit (Boston, MA; November
13-15)
Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical
Development
Abstract Title: DNA Medicines Vaccine Platform for both
Prophylactic and Therapeutic Applications: Case Studies in Ebola
and Recurrent Respiratory Papillomatosis
Abstracts from these conferences will be made available on
INOVIO's website following each presentation.
About INOVIO
INOVIO is a biotechnology company
focused on developing and commercializing DNA medicines to help
treat and protect people from HPV-related diseases, cancer, and
infectious diseases. INOVIO's technology optimizes the design and
delivery of innovative DNA medicines that teach the body to
manufacture its own disease-fighting tools. For more information,
visit www.inovio.com.
Contacts
Media: Jennie
Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302297797.html
SOURCE INOVIO Pharmaceuticals, Inc.
